Mallia Therapeutics GmbH

https://www.mallia-therapeutics.com

Mallia Therapeutics GmbH is a biopharmaceutical company focused on developing novel treatments for patients suffering from hair loss. The Company was founded in 2023 in Erlangen, Germany, and is led by an experienced management team and worldwide leading experts in the field of CD83, with more than 60 CD83-related publications and 20 years of experience in the field. With sCD83, a potential treatment for hair loss in preclinical development, Mallia aims to enter the multi-billion-dollar alopecia market and provide patients with a safe and effective topical treatment. *

	Start	2023-07-03 established (s-off)
	Predecessor	University Hospital Erlangen-Nürnberg (Universitätsklinikum)
	Industry	BIOTECH
	Industry 2	sCD83 (Mallia Therapeutics, soluble form of human CD83 protein)
	Person	Gröppel, Manfred (Mallia Therapeutics 202307 CEO + Co-Founer before Immunic + 4SC)
	Person 2	Steinkasserer, Alexander (Univ Erlangen-Nürnberg 202307 Head Dept Immune Modulation + Mallia Therapeutics)

	Region	Erlangen
	Country	Germany
	Street	91 Henkestr.
	City	91025 Erlangen
		Address record changed: 2023-07-18

Basic data	Employees	n. a.

		* Document for »About Section«: Mallia Therapeutics GmbH. (7/11/23). "Press Release: Mallia Therapeutics Secures Seed Funding for its Novel Topical Treatment to Induce Hair Growth via Immune Modulation". Erlangen.

		Record changed: 2024-12-29

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Mallia Therapeutics GmbH

[1] Mallia Therapeutics GmbH. (7/11/23). "Press Release: Mallia Therapeutics Secures Seed Funding for its Novel Topical Treatment to Induce Hair Growth via Immune Modulation". Erlangen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]